Formulation and Evaluation of Nanosuspension Formulations of Ramipril using Hydrophilic Polymers
DOI:
https://doi.org/10.37285/ijpsn.2015.8.1.5Abstract
Nanosuspensions provide convenient formulations for improving the bioavailability and drug delivery. The objective of the investigation was to develop stable nanosuspension formulation of ramipril, with minimum surfactant concentration that could improve its solubility, stability and oral bioavailability. Ramipril is a potent antihypertensive drug, which act by inhibiting the angiotensin-converting enzyme. Nanosuspension was developed by antisolvent precipitation followed by high-pressure homogenization using hydrophilic polymers such as HPMC E5, HPMC E15, PVP K30, PVP K25, and PVA. The resulting nanosuspension was transformed into dry powder by freeze-drying process. Among all five formulations a formulation was choosen on the basis of results obtained from comparative study between different polymers based nanosuspension formulation of ramipril. The nanosuspension prepared was then evaluated for particle size, polydispesivity index, zeta potential, entrapment efficiency, saturated solubility study, scanning electron microscopy, differential scanning colorometry, and X ray diffraction. The combination of soya lecithin and pluronic F-68 as stabilizers yield nanosuspension with the smallest average particle size. The formulation of ramipril based on HPMC E 15 (Formulation B) shown enhanced dissolution rate. In which more than 60% of the drug was dissolved in the first 20 min compared to less than 25% of the pure drug within the same time period. The increase in the in vitro dissolution rate, nano size may favourably affect bioavailability.
Downloads
Metrics
Keywords:
Ramipril, Antisolvent precipitation, High-pressure homogenization, Nanosuspensions, Lyophilisation.
Downloads
Published
How to Cite
Issue
Section
References
Arunkumar, N., Decarman, M. and Rani, C (2010). Dissolution Enhancement of Atorvastatin Calcium by Nanosuspension Technology. J Pharm Res. 3: 1903-1906.
Bernhard, H.L. and Muller R.H (1999). Lab Scale Productoion Unit Design for Nanosuspensions of Spraringly Soluble Cytotoxic Drugs. Pharm Sci and Tech Today. 2(8): 336-339.
Boghra, R.J., Kothawade, P. C., Belgamwar, V.S., Nerkar, P. P., Tekade, A. R. and Surana, S. J (2011). Solubility, Dissolution Rate and Bioavailability Enhancement of Irbesartan by Solid Dispersion Technique. Chem Pharm Bull. 59(4): 438-441.
Doulabi, M.F.S. and Mohsen-Nia, M (2013). Magnetic Cobalt- Zinc Ferrite/ Pvac Nanocomposite: Synthesis and Charactorization. Iran Polym J. 22(1): 09-14.
Dubernet, C., Couvreur, P. and Puisieux, F (1995). Controlled Drug Delivery with Nanoparticles: Current Possibilities and Future Trends. Eur J Pharm Biopharm. 41: 2-13.
Grau, M.J., Kayser, O. and Muller, R.H (2000). Nanosuspensions of Poorly Soluble Drugs: Reproducibility of Small Scale Production. Int J Pharm. 196(2): 155-157.
Griensven, J.M.V., Schoemaker, R.C., Cohen, A.F., Luus, H.G., Grafe, M.S. and Rothig, H.J (1995). Pharmacokinetics, Pharmacodynamics and Bioavailability of the ACE inhibitor Ramipril. Eur. J. Clin. Pharmac. 47: 513-518.
Hancock, B. C., Carlson, G. T., Ladipo, D. D., Langdon, B. A. and Mullarney, M. P., (2002). Comparison of the Mechanical Properties of Thecrystalline and Amorphous forms of a Drug Substance. Int J Pharm. 241(1): 73-85.
Hecq, J., Deleers, M., Fanara, D., Vranckx, H. and Amighi, K (2005). Preparation and Characterization of Nanocrystals for Solubility and Dissolution Rate Enhancement of Nifedipine. Int J Pharm, 299(1-2): 167-177.
Hussain, M.R., Devi, R.R. and Maji, T.K (2012). Controlled Release of Urea from Chitosan Microspheres Prepared by Emilsification and Cross-Linking Method. Iran Polym J. 21(8): 473-479.
In-Hwan, B. and Min-Soo, K (2012). Improved Supersaturation and Oral Absorption of Dutasteride by Amorphous Solid Dispersions. Chem Pharm Bull. 60(11): 1468-1473.
Kipp, J.E., Wong, J.C., Doty, M.J. and Rebbeck, C.L (2003). Micro-Precipitation Method for Preparing Submicron Suspensions. US Patent 6: 607-784.
Lee, M. K., Kim, M. Y., Kim, S. and Lee, J (2009). Cryoprotectants for Freeze Drying of Drug Nanosuspension: Effect of Freezing rate. J Pharm Sci. 98(12): 4808-4017.
Levitt, D.G. and Schoemaker, R.C (2006). Human Physiologically based Pharmacokinetic Model for ACE inhibitors: Ramipril and Ramiprilat. BMC Clin. Pharmac. 6(1): 6-1.
Malik, I.S., Bhatia, J. and Kooner, J.S (2001). Is Ramipril Cost-Effective as well as Clinically Useful in Reducing Cardiovascular Risk? J Am Coll Cardiol. 37: 511A-512B.
Müller, R. H., Jacobs, C. and Kayser, O (2001). Nanosuspensions as Particulate Drug Formulations in Therapy Rationale for Development and what we can Expect for the Future. Adv Drug Deliv Rev. 47(1): 3-19.
Müller, R. H. and Peters, K (1998). Nanosuspensions for the formulation of Poorly Soluble Drugs Preparation by a Size-Reduction Technique. Int J Pharm. 160(2): 229-237.
Raval, A. J. and Patel, M. M (2011). Preparation and Characteri-Zation af Nanoparticles for Solubility and Dissolution rate Enhancement of Meloxicam. Int R J Pharm. 1(2): 42-49.
Yang, C., Xu, X., Wang, J. and An, Z (2012). Use of The Co-Grinding Method to Enhance The Dissolution Behavior of A Poorly Water Soluble Drug: Generation of Solvent free Drug Polymer Solid Dispersion. Chem Pharm Bull. 60(7): 837-845.
Yusuf, S., Gerstein, H., Hoogwerf, B., Pogue, J., Bosch, J., Wolffenbuttel, B.H.R. and Zinman, B. (2001). HOPE study investigators, Ramipril and The Development of Diabetes. JAMA, 286(15): 1882-1885.
Yusuf, S., Sleight, P., Pogue, J., Bosch J., Davies R. and Dagenais G., (2000). Effects of an Angiotensin-Converting Enzyme Inhibitor, ramipril, on Cardiovascular Events in High-Risk Patients. The Heart outcomes Prevention Evaluation Study Investigators. N Engl J Med, 342(3): 145-153.
Zare, E. N. and Mansour, M.l (2014). Biodegradable Polyaninline/ Dextrin Conductive Nanocomposites: Synthesis Charactorization, and Study of Anitoxidant Acitvity and Sorption of Heavy Metal Ions. Iran Polym J, DOI:10.1007/s13726-014-0221-3
Zhang, X, Xia, Q. and Gu, N (2006). Preparation of All-Trans Retinoic Acid Nanosuspensions Using a Modified Precipitation Method. Drug Dev Ind Pharm. 32(7): 857-63.
